RAS野生型转移性结直肠癌抗表皮生长因子受体单抗维持治疗中国专家共识(2024版)  

Chinese expert consensus on maintenance treatment with anti-EGFR monoclonal antibody for RASwild-typemetastatic colorectal cancer(2024 edition)

作　　者：中国临床肿瘤学会结直肠癌专家委员会 徐瑞华[2] 张东生[2] Committee of Colorectal Experts,Chinese Society of Clinical Oncology;Xu Ruihua

机构地区：[1]不详 [2]中山大学肿瘤防治中心

出　　处：《中华胃肠外科杂志》2024年第4期316-325,共10页Chinese Journal of Gastrointestinal Surgery

摘　　要：对于接受标准一线治疗达到疾病控制的转移性结直肠癌(mCRC),后续治疗策略的制订应在维持疗效的同时注重改善患者生活质量。化疗联合抗表皮生长因子受体(EGFR)单抗是RAS野生型mCRC患者的标准一线治疗方案。当一线含抗EGFR单抗诱导治疗达到最佳疗效、且处于疾病缓解或稳定状态时,含抗EGFR单抗维持治疗方案可在维持疗效获益的同时,降低毒副反应和提高患者生活质量。本共识基于循证医学和临床实践,进一步明确抗EGFR单抗维持治疗的应用时机、方案选择、不良反应管理和后续策略选择,为抗EGFR单抗维持治疗提供临床应用规范化标准和指导,以期使患者的治疗最大化获益。For patients with metastatic colorectal cancer(mCRC)who achieve disease control during first-line standard therapy,post-induction strategies should emphasize on quality of life improvement while maintaining disease control.Chemotherapy combined with anti-epidermal growth factor receptor(EGFR)monoclonal antibody is the standard first-line treatment for RAS wild-type mCRC patients.After anti-EGFR-based first-line induction therapy achieves at least stable disease,anti-EGFR-based maintenance treatment could maintain disease control while keeping a good safety profile.Based on research evidence and clinical practice,the Chinese expert consensus on anti-EGFR-based maintenance strategy for RAS wild-type mCRC aims to futher clarify the treatment timing,regimen options,adverse reaction management and follow-up strategy,providing standardized guidance to maximize the clinical benefit in RAS wild-type mCRC.

关 键 词：结直肠肿瘤 转移性 RAS野生型 抗EGFR单抗 维持治疗 

分 类 号：R735.34[医药卫生—肿瘤]